PRIMARY PERITONEAL CARCINOMA

This early-phase study tests a new drug called IMGN151 in 256 adults with recurrent gynaecological cancers (ovarian, endometrial, cervical, and related cancers). The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to check safety, f…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than nivolumab alone for people with advanced clear cell ovarian, fallopian tube, or peritoneal cancer. About 46 participants will receive either one or both drugs to see if …

This study tests whether combining a cancer vaccine (DPX-Survivac) with an immunotherapy drug (pembrolizumab) and low-dose chemotherapy can shrink tumors in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine trains the immune system to attack …

This study tested a combination of two drugs, olaparib and cediranib, in 70 people with ovarian, peritoneal, or fallopian tube cancer that had returned after initial treatment. The goal was to see if the drugs could slow or stop tumor growth by blocking enzymes cancer cells need …

This study tests whether a new drug (ONC-392) combined with an existing immunotherapy (pembrolizumab) can shrink tumors or slow disease in people with ovarian cancer that no longer responds to platinum chemotherapy. About 58 adults with high-grade serous ovarian, primary peritone…

This study tests a new daily pill called sovilnesib for people with advanced ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to find the safest and most effective dose. About 120 participants will receive different doses to measure side effects an…

This early-phase study tests a new drug, AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment for people with advanced solid tumors that have stopped responding to standard therapies. The main goal is to find the safest dose and check for…

This study looks at 100 women with breast or gynecological cancer to see if their diet before starting chemotherapy affects levels of a protein called hepcidin. Researchers want to know if hepcidin levels are linked to how much of the planned chemotherapy dose patients actually r…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will store and study these samples over time to learn how cancer changes and why some treatments stop working. The goal is to improve future …

This pilot study tested whether a prehabilitation program—a set of exercises and health support before surgery—is practical and helpful for 22 women with advanced ovarian cancer. Participants received the program while undergoing chemotherapy to prepare for tumor-removal surgery.…